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The role of genetic variability in dementia with Lewy bodies (DLB) is now indisputable; however, data
regarding copy number variation (CNV) in this disease has been lacking. Here, we used whole-genome
genotyping of 1454 DLB cases and 1525 controls to assess copy number variability. We used 2 algorithms
to conﬁdently detect CNVs, performed a case-control association analysis, screened for candidate CNVs
previously associated with DLB-related diseases, and performed a candidate gene approach to fully
explore the data. We identiﬁed 5 CNV regions with a signiﬁcant genome-wide association to DLB; 2 of
these were only present in cases and absent from publicly available databases: one of the regions
overlapped LAPTM4B, a known lysosomal protein, whereas the other overlapped the NME1 locus and
SPAG9. We also identiﬁed DLB cases presenting rare CNVs in genes previously associated with DLB or
related neurodegenerative diseases, such as SNCA, APP, andMAPT. To our knowledge, this is the ﬁrst study
reporting genome-wide CNVs in a large DLB cohort. These results provide preliminary evidence for the
contribution of CNVs in DLB risk.
 2019 Elsevier Inc. All rights reserved.1. Introduction
Dementia with Lewy bodies (DLB) is a common and complex
form of neurodegenerative disease, and its diagnosis can often be
complicated by phenotypic similarities with Alzheimer’s disease
(AD), Parkinson’s disease (PD), or even frontotemporal dementia
(FTD) (Claassen et al., 2008; Heidebrink, 2002). A more accurate
DLB diagnosis is usually obtained by integrating clinical and path-
ological data from brain autopsy (McKeith et al., 2017).
Genetic studies in DLB have been limited, certainly in compar-
ison with studies on AD or PD, for a number of reasons, most
notably because DLB has not been historically considered a genetic
disease, given the lack of multiplex kindreds where the disease
segregates. In addition, large cohorts of patients are difﬁcult to
collect given the frequency of the disease and the rate of misdiag-
nosis. Despite this, recent studies have conclusively shown that
there is a role for genetics in the etiology of DLB (Bras et al., 2014;
Guerreiro et al., 2018, 2016; Nalls et al., 2013; Peuralinna et al.,
2015). Exome sequencing studies have been performed in small
cohorts, as have case studies and Sanger sequencing of speciﬁc
target genes (Clark et al., 2009; Geiger et al., 2016; Keogh et al.,
2016; Koide et al., 2002; Ohtake et al., 2004). Copy number varia-
tion (CNV) has not been assessed thus far in DLB, particularly in an
unbiased manner and at a genome-wide level.
CNVs have been widely studied in a number of neurological
conditions, particularly in developmental phenotypes such as
schizophrenia and autism (Glessner et al., 2009; Marshall et al.,
2017; McCarthy et al., 2009) where several microdeletions and
microduplications (100e600 kb) have been found to be associatedwith both diseases (Bassett et al., 2017; Cook et al., 1997; McCarthy
et al., 2009; Stefansson et al., 2008; Weiss et al., 2008). In these
phenotypes, CNVs play a prominent role in the disease genetic
architecture.
Several studies have analyzed CNVs in AD, where APP duplica-
tions have been unequivocally shown to cause disease (Delabar
et al., 1987; Ghani et al., 2012; Swaminathan et al., 2011, 2012;
Zheng et al., 2014, 2015). In PD, pathogenic CNVs are also known
to occur in SNCA, PARK2, PINK1, and PARK7 (Bonifati et al., 2003;
Chartier-Harlin et al., 2004; Ibáñez et al., 2004; Lesage et al.,
2008; Marongiu et al., 2007; Waters and Miller, 1994). Together,
these data show that CNVs are an important mutational event in
neurological conditions.
Here, we report the ﬁrst genome-wide analysis of CNVs in DLB in
a large cohort of patients, many of which with neuropathology
diagnoses of DLB. We performed a case-control association study
that was complemented by discovery stage analyses guided by
candidate genes and CNVs previously reported as being associated
with DLB-related neurodegenerative diseases.
2. Materials and methods
2.1. Sample selection
A total of 1454 patients diagnosed with DLB and of European
ancestry were selected for this study. Diagnosis of DLB was made
according to clinical or pathological criteria (McKeith et al., 2005).
Brieﬂy, these included 298 clinically diagnosed and 1156 neuro-
pathologically diagnosed cases. Detailed sample and processing
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Data from 1525 control samples were obtained from The Genetic
Architecture of Smoking and Smoking Cessation study
(phs000404.v1.p1) publicly available at the database of genotypes
and phenotypes (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id¼phs000404.v1.p1). Supplementary Fig. 1
shows an overview of the study design, different quality control
(QC) steps, and analyses performed.2.2. Genotyping, quality control, and CNV calling
Seven hundred ﬁfty-four DLB samples were genotyped on
HumanOmni2.5Exome-8 v1.0.B Illumina arrays, and 700 DLB
samples were genotyped using Inﬁnium OmniExpress-24 v1.2.A1
Illumina arrays (Illumina, Inc, CA, USA). Control samples were
genotyped on HumanOmni2.5-4 v1.D arrays (Illumina, Inc, CA,
USA). Intensity ﬁles were analyzed using GenomeStudio v2011.1
software (Illumina, Inc, CA, USA) along with the respective man-
ufacturer’s cluster ﬁles. QC procedures were performed in
GenomeStudio (GS) before CNV analysis as described by Jarick
et al. (Jarick et al., 2014). In short, samples with call rates lower
than 0.97 were ﬁltered out. SNP statistics were recalculated
following visual inspection of B allele frequency (BAF) and log R
ratio (LRR) plots. SNPs with GenTrain scores below 0.7 were
excluded. Finally, samples with substantial cryptic relatedness
scores (PI_HAT > 0.1) were removed, as previously described
(Guerreiro et al., 2018).
CNV calls were generated using 2 different algorithms: cnvPar-
tition v2.3.0 (Illumina, Inc) and PennCNV v1.0.4 (Wang et al., 2007).
CNV calling based on cnvPartition was performed by GS with
default parameters. For PennCNV, probe positions, LRR, and BAF
values for samples that passed QC procedures were exported from
GS. Population frequency of the B allele (PFB) ﬁles was calculated
for each array separately. All smoking cessation samples were used
to generate CNVs in cnvPartition and PennCNV, but only a subset of
the best performing 700 samples was used for the compilation of
the PFB ﬁle in PennCNV to match the number of samples used for
cases. PennCNV GC-model ﬁles were then created based on these
PFBs. Finally, CNVs were inferred by PennCNV using the hidden
Markovmodel and the GC-model for wave adjustment. Calls for the
X chromosome were generated separately. Chromosome Y SNPs
were not analyzed.2.3. CNV quality control and analysis
To improve the quality of CNVs, only calls generated by both
algorithms were kept, whereas calls made by a single algorithm or
calls of opposing type (e.g., assigned as a deletion by one algo-
rithm and as duplication by the other) were discarded. Adjacent
CNVs were merged if the length of the sequence between them
was smaller than 50% of the length of the larger CNV (Mok et al.,
2016). CNVs were excluded if they were overlapping telomeres,
centromeres, known segmental duplications, the immunoglob-
ulin, or T cell receptor loci. Samples having LRR SD > 0.28, BAF
drift > 0.002, waviness factor > 0.04, or having more CNV calls
than 3*SD þ median were excluded (Marshall et al., 2017; Need
et al., 2009).
To identify potentially pathogenic CNVs, we analyzed CNVs
spanning known genes. We used the database of genomic variants
(DGV) (http://dgv.tcag.ca/dgv/app/home, accessed November 2017)
to determine the population frequency of CNVs (MacDonald et al.,
2014). This information was complemented with the frequency
from clinical samples available in DECIPHER v9.18 (https://decipher.
sanger.ac.uk/, accessed November 2017).2.4. Case-control association analysis
Case-control association analysis was implemented using Par-
seCNV (Glessner et al., 2013). Standard ParseCNV quality metrics
were used to ﬁlter out low-quality results. CNVs that were genome-
wide signiﬁcant [p-value< 5104 as suggested by (Glessner et al.,
2013)] had aminimum length of 50 kb, and passed visual inspection
in GS were selected for further analyses.
2.5. Candidate CNVs approach
CNVs previously described in AD (Ghani et al., 2012; Heinzen
et al., 2010; Swaminathan et al., 2011, 2012; Zheng et al., 2014,
2015), PD (Bademci et al., 2010; Liu et al., 2013; Mok et al., 2016;
Pankratz et al., 2011), and FTD (Gijselinck et al., 2008) were spe-
ciﬁcally investigated in these data (Supplementary Table 1). This
analysis was performed on the complete set of CNV results after QC,
disregarding the ﬁlters used for the case-control association anal-
ysis performed by ParseCNV.
2.6. Candidate genes approach
CNVs located in known AD, PD, FTD, and DLB genes were also
assessed (Brás et al., 2015; Guerreiro et al., 2013, 2015, 2018; Jansen
et al., 2015; Keogh et al., 2016; Koide et al., 2002; Ohtake et al.,
2004; Saitoh et al., 1995). Supplementary Table 2 lists all genes
studied using this approach.
3. Results
3.1. CNV calling and QC steps
After QC steps at the GS level, a total of 2819 samples (1294 cases
and 1525 controls) remained for further analyses. From the 754 DLB
samples genotyped with HumanOmni2.5 arrays, 616 (81.7%) sam-
ples were kept and from the 2,567,845 probes in this array,
2,496,600 (97.2%) passed QC. Six hundred seventy-eight (96.9%)
samples of the 700 samples genotyped with OmniExpress arrays
passed QC and from the 713,599 probes available in this chip,
698,680 (97.9%) probes remained. All controls from the Smoking
Cessation database had good quality genotypes (call rate > 0.97)
and, consequently, no samples were excluded, and 2,390,384
(97.8%) of the 2,443,177 probes were kept.
After combining the results obtained by the 2 CNV calling al-
gorithms (cnvPartition and PennCNV), excluding samples because
of their relatedness, and performing the PennCNV QC steps on the
LRR and BAF values and number of calls, a ﬁnal number of 2615
individuals (1187 DLB cases and 1428 control samples) and 80,416
CNVs were analyzed. All samples carrying CNVs were conﬁrmed to
be of European/North American ancestry by merging their data
with that of 1000 Genomes.
3.2. Case-control association analysis
Of the 494 CNV regions resulting from the ParseCNV analysis,
only 5 passed QC checks and were statistically signiﬁcant (Table 1).
Of these, 2 of the regionswere not present in our control population
or in public databases: the deletion overlapping LAPTM4B (p ¼
6.29  107) and the one overlapping SPAG9-NME1-NME2 (p ¼
2.72  104) (Fig. 1).
3.3. Candidate CNVs approach
Five CNVs previously associated with DLB-related neurodegen-
erative diseases were found in DLB patients (Table 1). Two of these
Table 1
Results from the three types of analyses
Genes Location CNV p-value Cases
(Neuroa)
Controls Cases
frequency
Controls
frequency
DGV
frequency
DECIPHER
frequency
Case-control association analysis
ADGRG7,TFG chr3:100,357,671-100,439,759 Gain 8.93  105 21 (18) 13 1.77  102 9.10  103 1.43  102 2.09  102
PDZD2 chr5:32101,400-32,106,628 Gain 2.94  106 14 (12) 0 1.18  102 0 3.00  104 1.69  104
LAPTM4B chr8:98755,434-98,800,334 Loss 6.29  107 12 (6) 0 1.01  102 0 0 0
MSR1 chr8:15948,235-16,021,468 Loss 1.20  104 13 (7) 4 1.10  102 2.80  103 4.30  103 7.10  103
NME1,NME1-NME2,SPAG9 chr17:49,177,096-49,231,786 Loss 2.72  104 9 (4) 0 7.58  103 0 0 0
Candidate CNVs approach
CSMD1 chr8:4,033,908-4,126,540 Loss 2.89  102b 3 (2) 0 2.53  103 0 3.00  104 0
DDX11,OVOS2 chr12:31,249,834-31,407,303 Gain 1.41  102b 4 (2) 0 3.37  103 0 4.61  102 0
CYFIP1,GOLGA8I,NIPA1,
NIPA2,TUBGCP5,WHAMML1
chr15:22,750,305-23,272,733 Gain na 5 (5) 8 4.21  103 5.60  103 2.50  103 1.86  103
CHRNA7,OTUD7A chr15:31,932,865-32,515,849 Loss or Gain na 6 (5) 13 5.05  103 9.10  103 6.90  103 8.79  103
ASPHD1,BOLA2,C16orf54,CDIPT,CDIPT-AS1,
KIF22,MAZ,MVP,PAGR1,PRRT2,QPRT,SEZ6L2,
SPN,ZG16
chr16:29,595,483-29,912,902 Gain na 1 (1) 0 8.42  104 0 0 1.69  104
Candidate genes approach
DNAJC6,LEPR,LEPROT chr1:65,854,556-65,955,725 Gain na 1 (0) 1 8.42  104 7.00  104 1.72  104 2.53  103
SNCA,SNCA-AS1,GPRIN3,MMRN1,CCSER1 chr4:90,035,549-91,420,358 Gain na 1 (1) 0 8.42  104 0 6.42  104 0
PARK2 chr6:161,601,162-163,259,260 Loss or Gain na 13 (8) 28 1.10  102 1.96  102 2.30  103 1.69  101
GABRB3,GABRA5,GABRG3 chr15:26,996,126-27,220,713 Gain na 1 (1) 0 8.42  104 0 0 1.18  103
MAPT,CRHR1,KANSL1,KANSL1-AS1,
MAPT-AS1,MAPT-IT1,SPPL2C,STH
chr17:43,661,362-44,345,063 Gain na 2 (0) 0 1.68  103 0 1.03  104 1.18  103
APP,ADAMTS1,ADAMTS5,ATP5J,CYYR1,
CYYR1-AS1,GABPA,JAM2,MRPL39
chr21:25,063,840-28,522,487 Gain na 1 (0) 0 8.42  104 0 0 0
CHCHD10,ADORA2A,ADORA2A-AS1,
C22orf15,CABIN1,CES5AP1,DDT,DDTL,
DERL3,DRICH1,GGT1,GGT5,GSTT1,GSTT1-AS1,
GSTT2,GSTT2B,GSTTP1,GSTTP2,GUCD1,
GUSBP11,IGLL1,LRRC75B,MIF,MIF-AS1,
MMP11,POM121L9P, RGL4,SLC2A11,SMARCB1,
SNRPD3,SPECC1L,SUSD2,UPB1,VPREB3,
ZDHHC8P1,ZNF70
chr22:23,690,325-25,011,417 Gain na 1 (1) 0 8.42  104 0 6.00  104 1.18  103
CYP2D6,NDUFA6-AS1 chr22:42,522,613-42,531,210 Loss or Gain na 1 (1) 4 8.42  104 2.80  103 2.20  101 3.00  102
All genomic coordinates are for the genome assembly hg19.
a Neuropathological diagnosis; naenot applicable; p-valuedthese were calculated including all cases (not only neuropathologically conﬁrmed cases).
b p-values resulting from the case-control association analysis.
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the patient group, and the remaining 3 are described in public
databases and are detailed next. The duplication identiﬁed on
chromosome 12 overlapping DDX11 and OVOS2 has a frequency 10-
fold higher in DGV than in the DLB cohort. The 16p11.2 micro-
duplication found in one DLB patient has a frequency of 1.69  104
in the DECIPHER database but does not occur in any control samples
or in the DGV database. One of the CNVs that was previously
signiﬁcantly associated with AD locates at chr8:2,792,874-
4,852,328 and overlaps CSMD1 (Swaminathan et al., 2011). CSMD1
has frequent deletions and duplications spanning thewhole gene as
reported in DGV. Our results agree with this: at this locus, we
identiﬁed over 100 deletions in cases and controls. One region in
the gene has a deletion in 3 cases and in no controls and this CNV
showed a suggestive signiﬁcance in our DLB case-control associa-
tion analysis. Therefore, we only report this shorter region in
Table 1.
3.4. Candidate genes approach
We investigated CNVs in genes known to be associated with
diseases that are related to DLB (Supplementary Table 2) and
identiﬁed a total of 8 CNVs (Table 1). These included one duplica-
tion in APP occurring in a clinically diagnosed case. This large
duplication is not present in the databases or in the control cohort.
Two DLB subjects were found to carry duplications spanningMAPT,
and one neuropathologically diagnosed patient was found to carry a
SNCA duplication (Fig. 2). PARK2 was found to have many copy
number losses and gains in controls (n ¼ 28) and cases (n ¼ 13) but
none were homozygous. A duplication including CHCHD10was also
identiﬁed in a neuropathologically diagnosed DLB patient. No CNVs
were identiﬁed in GBA, the gene presenting the strongest associa-
tion with DLB.
4. Discussion
We performed a systematic analysis of CNVs in a large cohort of
DLB patients using 3main approaches. The ﬁrst of these approaches
was a case-control association analysis, which resulted in 5 signif-
icant CNV regions that have not been previously described as
associated with the disease. The most signiﬁcant result from this
analysis was a deletion spanning a lysosome-associated trans-
membrane protein, LAPTM4B. Intraneuronal alpha-synuclein
clearance likely occurs through a variety of mechanisms to main-
tain protein homeostasis. However, recent data have highlighted
the importance of lysosomal pathways for degradation of this
protein (Webb et al., 2003). Interestingly, a member of the same
protein family, LAPTM5, was one of the top hits for incidental DLB inFig. 1. Schematic representation of statistically signiﬁcant CNVs resulting from the case-c
overlapping LAPTM4B in A; and SPAG9/NME1 in B. Known transcripts are represented at the
according to the genotyping array (red: OmniExpress, blue: Omni2.5 M, green: Omni2.5 M fo
area represents the associated region that is genome-wide signiﬁcant. (For interpretation of
this article.)a recent network analysis study (Santpere et al., 2018). Althoughwe
cannot directly link this CNV to the development of DLB in these
cases, it is interesting that a lysosomal enzyme is the top hit in our
association analysis, given the prominent role of the lysosome in
Lewy body diseases. In fact, a strong GWAS hit for DLB is GBA, a gene
involved in lysosomal lipid storage disorders.
Also associated with DLB and absent from publicly available da-
tabaseswas adeletionoverlapping theNME1 locus.NME1 is involved
in purine metabolism, which has been reported to be disrupted in
AD, PD, and CreutzfeldteJakob disease. NME1mRNAwas also found
to be reduced in these diseases (Ansoleaga et al., 2015, 2016; Garcia-
Esparcia et al., 2015). Here, we identiﬁed a deletion at the 30-end of
NME1, which could be consistent with a reduced expression of the
gene in DLB, although this was not tested in the present study.
Using a candidate gene approach where we analyzed genes
known to have a role in DLB and DLB-related diseases, we identiﬁed
several CNVs of potential interest. The hallmark of DLB at autopsy is
the accumulation of alpha-synuclein protein within neurons and
their processes, termed Lewy bodies and Lewy neurites (Spillantini
et al., 1997). Variants in the SNCA gene, which encodes alpha-
synuclein, have been previously associated with the risk of devel-
oping DLB (Bras et al., 2014; Guerreiro et al., 2018). In addition to
point mutations, CNVs including SNCA are known to cause PD, and
over the past years, evidence has suggested that this gene may also
be duplicated in DLB. Nishioka et al. identiﬁed a PD family with a
duplication spanning all of SNCA and MMRN1 where the proband
was later neuropathologically diagnosed as DLB (Nishioka et al.,
2006; Obi et al., 2008). Four neuropathologically diagnosed DLB
cases presented a large duplication from DSPP to PDLIM5 including
SNCA, 3 of these were heterozygous and 1 was homozygous
(Ikeuchi et al., 2008). A duplication in SNCAwas also described in a
probable DLB patient in a study with 99 cases (Meeus et al., 2012).
Here, we add to this body of evidence, by identifying another pa-
tient neuropathologically diagnosed with DLB carrying a SNCA
duplication. In our DLB cohort, this duplication shows a similar
frequency to that provided by DGV. However, the frequency re-
ported in DGV results from 2 entries in that database.When looking
inmore detail at these 2 entries, they are actually duplicated entries
from the same Human Genome Diversity Project (HGDP) sample
from Cambodia (HGDP00721). Given that information for each
HGDP samples is limited to sex of the individual, population, and
geographic origin, it is possible this sample originated from a PD or
DLB patient or from an asymptomatic carrier, as these have previ-
ously been reported, with SNCA multiplications having particularly
low penetrance levels in Asian populations (Ahn et al., 2008;
Nishioka et al., 2006). It is also possible the duplication reported
is an artifact caused by the creation or passage of the lymphoblast
cell lines used to extract DNA (Simon-Sanchez et al., 2007).ontrol analysis that were not found in controls or publicly available databases. CNVs
bottom of each panel. Passing QC SNPs used for the CNV calling are depicted by color
r controls). CNVs (duplications) are depicted as bars above the genes. The gray shadow
the references to color in this ﬁgure legend, the reader is referred to the Web version of
Fig. 2. Duplication identiﬁed at the SNCA locus. Log R ratio and B allele frequency plots of the CNV identiﬁed in the SNCA locus. Each point represents an SNP according to location in
chromosome 4 (position on X axis). The genomic duplication is indicated by an increase in log R ratio and B allele frequency clusters outside the expected values of 1 (B/B), 0.5 (A/B),
and 0 (A/A). Genes are represented at the bottom as black bars. SNPs inside the CNV region are represented in red, SNPs outside the CNV region are represented in blue, and SNPs in
SNCA are represented in green. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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CHCHD10, a gene previously shown to cause FTD and/or amyo-
trophic lateral sclerosis (Zhang et al., 2015). However, given that
disease-associated CHCHD10 mutations are loss-of-function
(Perrone et al., 2017), it is not clear whether a duplication of the
gene would be pathogenic.
GABRB3 is a gamma-aminobutyric acid (GABA) receptor that was
reported to be associated with DLB in a recent GWAS but did not
survive independent replication (Guerreiro et al., 2018). However,
loss of GABA receptors could underlie the typical visual hallucina-
tions in DLB (Khundakar et al., 2016), and because of this, we spe-
ciﬁcally looked at CNVs in GABRB3 and identiﬁed a duplication in
one case. Given the GWAS results previously mentioned, the CNV
detected here and the fact that GABA receptor neurotransmission is
altered in DLB (Santpere et al., 2018), it is tempting to speculate that
genetic variability in GABA receptors may, in fact, modulate risk for
DLB.
We identiﬁed 2 clinically diagnosed DLB samples with MAPT
duplications (Fig. 3). MAPT was not found to be signiﬁcantly asso-
ciated with DLB in recent GWAS (Bras et al., 2014; Guerreiro et al.,
2018), but the MAPT H1 haplotype was previously described as a
possible risk factor for DLB (Cervera-Carles et al., 2016; Labbé et al.,
2016) and is a well-known genetic risk factor for PD. Previous
studies of small cohorts of FTD patients have not revealed causative
MAPT duplications (Lladó et al., 2007; Skoglund et al., 2009) but the
screening of French FTD patients including multiplex families led to
the identiﬁcation of a heterozygous partial deletion of MAPT
(Rovelet-Lecrux et al., 2009) and a 17q21.31 microduplication in an
atypical FTD case (Rovelet-Lecrux et al., 2010). More recently,MAPT
duplications were shown to increase expression ofMAPTmRNA and
were found to cause tangle pathology without Ab deposition in
probable AD patients (Le Guennec et al., 2017).
PARK2 homozygous CNVs are the most common copy number
cause of PD, accounting for more than 50% of all pathogenic
mutations in the gene and more frequently affecting the region
between exons 2 and 7 (Hedrich et al., 2004; Kim et al., 2012). Our
results showed no signiﬁcant differences in the frequency of
heterozygous CNVs overlapping PARK2 between DLB cases and
controls, similar to the ﬁndings by Kay et al. in PD (Kay et al.,
2010). In addition, we did not ﬁnd any homozygous PARK2 CNVs
suggesting that CNVs in this gene do not play a causative role in
DLB.
APP duplications are known to cause AD (Delabar et al., 1987;
Ghani et al., 2012; Swaminathan et al., 2011, 2012; Zheng et al.,
2014, 2015). The sample carrying an APP duplication in our cohorthas a clinical diagnosis of DLB without neuropathological conﬁr-
mation; it is therefore possible that this is an AD case misdiagnosed
as DLB. However, there have been reports in the literature of DLB
cases associated with APP duplications. For example, in a French
family presenting with a diverse phenotype, APP duplication was
associated with DLB conﬁrmed by neuropathological ﬁndings
(Guyant-Marechal et al., 2008). Similarly, one case with Lewy
bodyevariant AD was reported in a multigenerational dementia
family from the Netherlands (Sleegers et al., 2006). DLB cases
frequently present Ab pathology at autopsy (Hepp et al., 2016), and
it has been suggested that Ab accumulation can trigger Lewy body
disease (Masliah et al., 2001).
There are 2main limitations in this study: ﬁrst, this is a relatively
small-sized cohort, which means we cannot conﬁdently assess as-
sociations of CNVs with low effect sizes on disease; second, we did
not perform independent replication of these ﬁndings, which pre-
cludes us from establishing deﬁnite associations or causes of dis-
ease. Despite these limitations, we report on the ﬁrst systematic
analysis of CNVs in a large cohort of DLB patients, using well-
established analytical practices. We identiﬁed potential disease
causing CNVs as well as potential novel candidate genes for DLB.
Despite this, our results suggest that it is unlikely that CNVs play a
signiﬁcant role in the pathogenesis of DLB.
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